Advertisement
Advertisement
U.S. markets close in 49 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Celldex Therapeutics, Inc. (CLDX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
37.84+0.51 (+1.37%)
As of 03:09PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close37.33
Open37.33
Bid37.59 x 1800
Ask37.69 x 800
Day's Range37.33 - 38.52
52 Week Range19.85 - 57.20
Volume267,605
Avg. Volume849,090
Market Cap1.77B
Beta (5Y Monthly)2.43
PE Ratio (TTM)N/A
EPS (TTM)-1.73
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est66.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CLDX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Celldex Therapeutics, Inc.
    Analyst Report: Pfizer Inc.Pfizer is a leading global developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Zacks

    Celldex Therapeutics (CLDX) Reports Q2 Loss, Lags Revenue Estimates

    Celldex (CLDX) delivered earnings and revenue surprises of -34.88% and 53.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    - Positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022 - - First patients dosed in Phase 2 chronic urticaria studies - HAMPTON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. “In late June, Celldex reported positive interim data from our ongoing Phase 1b study of barzolvolimab in chronic spontane

  • GlobeNewswire

    Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

    HAMPTON, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU) - cold urticaria (ColdU) and symptomatic dermographism (SD). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity.

Advertisement
Advertisement